Skip to main content
Media Coverage

‘Psychedelics-Inspired’ Meds For Depression, Anxiety, Addiction Producer Trims Q1 Net Loss YoY, Increases Cash On Hand [Benzinga]

By May 16, 2024No Comments

Enveric Biosciences reported it financial results on Wednesday for the first quarter of 2024 ended March 31, 2024. “We believe the first quarter of 2024 was a highly productive period for Enveric as the company continued to advance the development of the lead neuroplastogen drug candidate, EB-003, in preparation for an investigational new drug (IND) application and the expected initiation of a planned clinical development program,” said Joseph Tucker, Ph.D., director and CEO of Enveric. “EB-003 was designed specifically to address this major safety profile deficiency in the first-generation psychedelic approach to treating neuropsychiatric illness, and we are excited to advance its development.”

Full Article >>